CytomX Therapeutics Current Ratio 2014-2022 | CTMX

CytomX Therapeutics current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CytomX Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.20B $0.10B 2.05
2022-06-30 $0.23B $0.10B 2.34
2022-03-31 $0.27B $0.10B 2.61
2021-12-31 $0.31B $0.11B 2.92
2021-09-30 $0.24B $0.10B 2.42
2021-06-30 $0.27B $0.09B 2.90
2021-03-31 $0.40B $0.10B 4.08
2020-12-31 $0.32B $0.10B 3.21
2020-09-30 $0.34B $0.10B 3.34
2020-06-30 $0.37B $0.10B 3.71
2020-03-31 $0.40B $0.11B 3.77
2019-12-31 $0.30B $0.09B 3.54
2019-09-30 $0.34B $0.08B 4.40
2019-06-30 $0.37B $0.08B 4.66
2019-03-31 $0.41B $0.10B 4.21
2018-12-31 $0.45B $0.10B 4.55
2018-09-30 $0.47B $0.09B 5.48
2018-06-30 $0.37B $0.08B 4.41
2018-03-31 $0.37B $0.07B 5.27
2017-12-31 $0.39B $0.06B 6.36
2017-09-30 $0.38B $0.07B 5.28
2017-06-30 $0.34B $0.06B 5.62
2017-03-31 $0.17B $0.04B 4.50
2016-12-31 $0.19B $0.04B 5.26
2016-09-30 $0.18B $0.02B 7.74
2016-06-30 $0.20B $0.02B 8.98
2016-03-31 $0.19B $0.02B 10.85
2015-12-31 $0.19B $0.02B 12.06
2015-09-30 $0.12B $0.01B 8.24
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B 0.00
2014-09-30 $0.00B 0.00
2013-12-31 $0.01B $0.00B 2.22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.175B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00